MedWatch

A part of Watch Media

Demant to release quarterly figures from May onwards

In order to become more transparent, hearing aid giant Demant will soon release revenue figures on a quarterly basis.

Photo: Demant / PR
by christian bundgaard, translated by catherine brett

Demant is making it easier to get an overview of the firm’s key figures.

In a stock exchange notification, the company has announced that it will be giving investors and interested parties a more detailed overview of the group’s different business areas and segments, starting with the next quarterly report.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Foto: Russell Cheyne/Reuters/Ritzau Scanpix

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

  1. US to start using Bavarian vaccine stockpile
  2. GN purchase story is very speculative, says analyst
  3. Novo Nordisk invests additional millions of dollars in new manufacturing facilities
  4. CHMP to remove 100 generic medicines from market
  5. Germany orders 40,000 monkeypox vaccines from Bavarian Nordic
  6. Rumored purchase of GN Group could mean divestment of hearing aid division, says media
  7. EMA publishes new plan to support antibiotic development
  8. New head of research at Astellas Gene Therapies: "Choosing the right indications is extra important"
  9. Dexcom is in talks to acquire device firm Insulet
  10. Bavarian Nordic ramps up monkeypox vaccine production
  11. Carb-X secures USD 370m in fight against antibiotic resistance
  12. Former Ambu CEO's equity investments end in USD 2m losses
  13. Jesper Høiland retires as chief commercial officer of Ascendis Pharma
  14. Monkeypox vaccine attracts interest for Bavarian as virus spreads
  15. Almirall announces Danish launch of MC2 Therapeutics-developed psoriasis cream

See all

Job

See all jobs

See all jobs